CV Sciences, Inc. (OTCQB:CVSI) announced its financial results for the second quarter of 2025, revealing stable revenue figures and notable improvements in gross margin and operational efficiency. The company recorded a revenue of $3.6 million for the quarter ended June 30, 2025, which is unchanged from the previous quarter but represents an 8% decrease from $4.0 million reported in Q2 2024.
The gross margin for CV Sciences in Q2 2025 reached 50.9%, marking the highest level since the third quarter of 2019. This reflects a significant increase from 46.0% achieved in Q1 2025, showcasing the company’s successful cost management and operational strategies.
CV Sciences reported a positive adjusted EBITDA of $0.1 million for the second quarter of 2025. This is a significant turnaround from an adjusted EBITDA loss of $0.3 million in Q1 2025 and a minor loss of $6,000 in Q2 2024. This positive result highlights the company's focus on improving its operational efficiency and strategy toward achieving consistent profitability.
The decline in overall revenue is mainly attributed to lower sales volumes caused by state regulatory challenges. The company noted that the total number of units sold decreased by 7.0%, coupled with a 2.8% decline in average sales prices. However, new products launched since January 2023 constituted 39% of total net revenue this quarter, with the introduction of 34 new products indicating a robust commitment to innovation and market adaptation.
Management expressed optimism for the second half of 2025, anticipating further improvements in gross margin and continued focus on organic growth. Efforts include in-sourcing production through the acquisition of Elevated Softgels, aimed at enhancing gross margins and streamlining operations. Additionally, ongoing product development and potential mergers and acquisitions are seen as vital steps to bolster revenue and shareholder value in a challenging regulatory environment.
CV Sciences reported revenue of $3.6 million for the second quarter of 2025, consistent with Q1 2025 but down from $4.0 million in the same quarter of 2024. The company achieved a gross margin of 50.9%, the highest since Q3 2019, indicating improving profitability.
In Q2 2025, CV Sciences reported a positive adjusted EBITDA of $0.1 million, a significant turnaround from an adjusted EBITDA loss of $0.3 million in Q1 2025 and a loss of $6,000 in Q2 2024. This marks the first positive adjusted EBITDA since Q2 2019, reflecting improved operational efficiency.
The decline in revenue from $4.0 million in Q2 2024 to $3.6 million in Q2 2025 was primarily attributed to lower sales volume, driven largely by regulatory pressures at the state level. Despite this, the company has been proactive in launching new products, which accounted for 39% of net revenue.
CV Sciences anticipates further improvements in gross margin in the latter half of 2025, driven by ongoing efforts in product development and the in-sourcing of production through the acquisition of Elevated Softgels, which could enhance overall profitability.
CV Sciences is actively working to mitigate regulatory risks by diversifying its product offerings and focusing on innovation in response to the uncertain regulatory landscape for the CBD category. This strategic focus may enhance product resilience and market adaptability.
As of the end of Q2 2025, CV Sciences reported a cash balance of $0.9 million, an increase from $0.5 million at the end of 2024. This improvement in cash position may provide the company with more operational flexibility as it navigates through growth opportunities.
CV Sciences launched 34 new products since January 2023, which contributed significantly to its revenue, demonstrating the company’s commitment to innovation and diversification in its product lines despite the challenges in sales volume.
The recent financial performance of CV Sciences, particularly the positive adjusted EBITDA and strong gross margin results, suggest that the company is on a path toward increased profitability and cash flow stability, which could enhance shareholder value in the evolving wellness market.